NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922

ALK is involved in the onset of several tumors. Crizotinib (Xalkori(TM)), a potent ALK inhibitor, represents the current front-line treatment for ALK+ NSCLC and shows great clinical efficacy. However, resistant disease often develops after initial response. ASP3026 is a novel second-generation ALK i...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Mologni, Luca, Ceccon, Monica, Pirola, Alessandra, Chiriano, Gianpaolo, Piazza, Rocco, Scapozza, Leonardo, Gambacorti-Passerini, Carlo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2015
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467397/
https://ncbi.nlm.nih.gov/pubmed/25749034
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia